Abstract
New triarylpyrazole derivatives, substituted with basic side chain, polar group or heterocyclic ring were designed and synthesized. Nineteen compounds were tested for their in vivo uterotrophic activity. Animals treated with compounds 9, 15a, 15c, 19a, 19f, 20a, and 21b showed pronounced increase in uterine weight. It is worth mentioning that compound 19f was more active than estradiol as an estrogenic compound as evidenced by the increased dry uterine weight. Additionally, compound 19a produced 128.25% increase in dry uterine weight relative to estradiol. On the other hand, eight compounds were screened for their in vivo antiuterotrophic activity. Animals treated with compounds 5e, 5f, 8, and 13b showed pronounced decrease in uterine weight. The highest antiuterotrophic effect was observed in mice receiving compound 13b, which was as potent as the positive control, tamoxifen as evident by the decrease in the uterine wet weight.
Similar content being viewed by others
References
Angerer Ev, Knebel N, Kager M, Ganss B (1990) 1-(Aminoalkyl)-2-phenylindoles as novel pure estrogen antagonists. J Med Chem 33:2635–2640
Awazu Y, Mizutani A, Nagase Y, Tsuchiya S, Nakamura K, Kakoi Y, Kitahara O, Takeuchi T, Yamasaki S, Miyamoto N, Iwata H, Miki H, Imamura S, Hori A (2013) Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase. Cancer Sci 104:486–494
Bai Z, Gust R (2009) Review: breast cancer, estrogen receptor and ligands. Arch Pharm (Weinheim) 342:133–149
Bayrack H, Demirbas A, Karaoglu SA, Demirbas N (2009) Synthesis of some new 1,2,4-triazoles, their Mannich and Schiff bases and evaluation of their antimicrobial activities. Eur J Med Chem 44:1057–1066
El-Deeb IM, Lee SH (2010) Design and synthesis of new potent anticancer pyrazoles with high FLT3 kinase inhibitory selectivity. Bioorg Med Chem 18:3961–3973
El-Tombary AA, Ismail KA, AboulWafa OM, Omar AMME, El-Reyini SH (1995) Synthesis of novel estradiol thiosemicarbazone derivatives as potential antiestrogens. Alex J Pharm Sci 9:147–152
Fink BE, Mortensen DS, Stauffer SR, Aron ZD, Katzenellenbogen JA (1999) Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chem Biol 6:205–219
Garcia-Segura LM, Azcoitia I, DonCarlos LL (2001) Neuroprotection by estradiol. Prog Neurobiol 63:29–60
Ghosh U, Ganessunker D, Sattigeri VJ, Carlson KE, Mortensen DJ, Katzenellenbogen BS, Katzenellenbogen JA (2003) Estrogenic diazenes: heterocyclic non-steroidal estrogens of unusual structure with selectivity for estrogen receptor subtypes. Bioorg Med Chem 11:629–657
Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M, Gustafsson JÅ (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87:905–931
Ismail KA, Abd El Aziem T (2001) Synthesis and biological evaluation of some novel 4H-benzopyran-4-one derivatives as nonsteroidal antiestrogens. Eur J Med Chem 36:243–253
Ismail KA, El-Tombary AA, AboulWafa OM, Omar A-MME, El Rewini SH (1996) Novel steroidal 1,4-diketones and pyridazine derivatives as potential antiestrogens. Arch Pharm Pharm Med Chem 329:433–437
Jain N, Xu J, Kanojia RM, Du F, Jian-Zhong G, Pacia E, Lai MT, Musto A, Allan G, Reuman M, Li X, Hahn D, Cousineau M, Peng S, Ritchie D, Russell R, Lundeen S, Sui Z (2009) Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms. J Med Chem 52:7544–7569
Kamal A, Shaik AB, Jain N, Kishor C, Nagabhushana A, Supriya B, Kumar GB, Chourasiya SS, Suresh Y, Mishra RK, Addlagatta A (2015) Design and synthesis of pyrazoleeoxindole conjugates targeting tubulin polymerization as new anticancer agents. Eur J Med Chem 92:501–513
Kankanala J, Latham AM, Johnson AP, Homer-Vanniasinkam S, Fishwick CWG, Ponnambalam S (2012) A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis. Br J Pharmacol 166:737–748
Katzenellenbogen BS, Katzenellenbogen Ja (2000) Estrogen receptor transcription and transactivation Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2:335–344
Katzenellenbogen BS, Miller MA, Eckert RL, Sudo K (1983) Antiestrogen pharmacology and mechanism of action. J Steroid Biochem 19:59–68
Kumar A, Pakrasi P (1995) Estrogenic and antiestrogenic properties of clomiphene citrate in laboratory mice. J Biosci 20:665–673
Kumar H, Saini D, Jain S, Jain N (2013) Pyrazole scaffold: a remarkable tool in the development of anticancer. Eur J Med Chem 70:248–258
Magarian RA, Overacre LB, Singh S, Meyer KL (1994) The medicinal chemistry of nonsteroidal antiestrogens: a review. Curr Med Chem 1:61–104
May M (1971) In: Turner R, Hebborn P (eds) Estrogenic and antiestrogenic agents in screening methods in pharmacology, vol 2, Ch. 6. Academic, New York, NY and London, 85–100
McDonnell DP, Wardell SE (2010) The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol 10:620–628
Mendelsohn ME, Karas RH (2005) Molecular and cellular basis of cardiovascular gender differences. Science 308:1583–1587
Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA (2011) Estrogen receptor β ligands: recent advances and biomedical applications. Med Res Rev 31:364–442
Mohareb RM, Abdallah AEM, Abdelaziz MA (2014) New approaches for the synthesis of pyrazole, thiophene, thieno[2,3-b]-pyridine, and thiazole derivatives together with their anti-tumor evaluations. Med Chem Res 23:564–579
Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618
Osipo C, Liu H, Meeke K, Jordan VC (2004) The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death. Exp Biol Med 229:722–731
Padilla-Banks E, Jefferson WN, Newbold RR (2001) The immature mouse is a suitable model for detection of estrogenicity in the uterotropic bioassay. Environ Health Perspect 109:821–826
Pirol ŞC, Çaliışkan B, Durmaz I, Atalay R, Banoglu E (2014) Synthesis and preliminary mechanistic evaluation of 5-(p-tolyl)-1-(quinolin-2-yl)pyrazole-3-carboxylic acid amides with potent antiproliferative activity on human cancer cell lines. Eur J Med Chem 87:140–149
Saripinar E, Guzel Y, Onal Z, Ilhan IO, Akcamur Y (2000) 4-(-4-methoxybenzoyl)-5-(-4-methoxyphenyl)-2,3-dihydro-2,3-furandione, it’s synthesis, thermolysis and Diels-Alder reactions with Schiff bases: Experimental data and calculations. J Chem Soc Pak 22:308–317
Shi JB, Tang WJ, Bao qi X, Li J, Li R, Liu XH (2015) Novel pyrazole-5-carboxamide and pyrazolepyrimidine derivatives: synthesis and anticancer activity. Eur J Med Chem 90:889–896
Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS, Katzenellenbogen JA (2000) Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-α-selective agonists. J Med Chem 43:4934–4947
Stauffer SR, Katzenellenbogen JA (2000) Solid-Phase synthesis of tetrasubstituted pyrazoles, novel ligands for the estrogen receptor. J Comb Chem 2:318–329
Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA, Katzenellenbogen BS (2002) Antagonists selective for estrogen receptor alpha. Endocrinology 143:941–947
Sun J, Lv X-H, Qiu H-Y, Wang Y-T, Du Q-R, Li D-D, Yang Y-H, Zhu H-L (2013) Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors. Eur J Med Chem 68:1–9
Thomas C, Gustafsson J-Å (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11:597–608
Vijaykumar D, Al-Qahtani MH, Welch MJ, Katzenellenbogen JA (2003) Synthesis and biological evaluation of a fluorine-18 labeled estrogen receptor-alpha selective ligand: [18F] propyl pyrazole triol. Nucl Med Bio 30:397–404
Wang KJ, Shi DQ, Sun LS, Jiang X, Lü YY, Dai J, Chen DY, Xu ZH, Jiang Q (2012) Association of estrogen receptor alpha gene polymorphisms with bone mineral density: a meta-analysis. Chin Med J 125:2589–2597
Xing M, Zhao T-T, Ren Y-J, Peng N-N, Yang X-H, Li X, Zhang H, Liu G-Q, Zhang L-R, Zhu H-L (2014) Synthesis, biological evaluation, and molecular docking studies of pyrazolyl-acylhydrazone derivatives as novel anticancer agents. Med Chem Res 23:3274–3286
Zheng Y, Zheng M, Ling X, Liu Y, Xue Y, An L, Gu N, Ji M (2013) Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors. Bioorg Med Chem Lett 23:3523–3530
Acknowledgements
The authors are thankful to N.M. Andijani for her assistance in in vivo experiments.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Ragab, M.A., Abd El Razik, H.A., Afify, E.A. et al. Design, synthesis, estrogenic and antiestrogenic activities of some triarylpyrazole derivatives. Med Chem Res 26, 2785–2808 (2017). https://doi.org/10.1007/s00044-017-1977-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-017-1977-8